


Product Name : PLB-1001
Cat. No. : PC-35732
CAS No. : 1440964-89-5
Molecular Formula : C₂₀H₁₅F₃N₈
Molecular Weight : 424.391
Target : c-Met (HGFR)
Solubility : 10 mM in DMSO



Biological Activity

PLB-1001 (Bozitinib, Vebreltinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable **MET kinase** inhibitor, potently inhibits MET activity by 95.1% at 2 uM.

Similar with crizotinib, PLB-1001 inhibited the phosphorylation of MET and STAT3, indicating a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways.

PLB-1001 demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells (METex14) in preclinical models.

PLB-1001 also exhibits clinical potential for precisely treating gliomas.

References

Hu H, et al. **Cell**. 2018 Oct 12. pii: S0092-8674(18)31250-9.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com